Nxera Pharma (4565) Corporate presentation summary

Business overview

• Technology-driven biopharma focused on specialty medicines in neurology, metabolic, and immunology/GI, with over 400 employees across five locations and a strong presence in Japan and globally.

• Annual revenues of $200m, $240m cash on hand, and over 1,500 patents granted, with a Tokyo Stock Exchange PRIME listing.

• Proprietary NxWave™ platform and StaR™ technology enable structure-based drug design, with over 100 GPCR structures solved.

• Bilingual, globally experienced management and agile, technology-enabled teams drive innovation and address major healthcare challenges.

Strategic roadmap and growth

• Built through strategic acquisitions (Arakis, Heptares, Idorsia Japan/Korea) and partnerships, generating steady revenue and a robust pipeline.

• Business model leverages upfront, milestone, royalty, and product sales, with a focus on out-licensing and commercialization.

• FY2025 objectives include JPY 17bn+ net product sales, in-licensing late-stage medicines, new partnerships, and positive operating profit if GPR52 option is exercised.

• Vision to achieve high growth and profitability by 2030, with royalties from WAVE1 and WAVE2 programs driving step-change in revenue.

Pipeline and partnerships

• Diverse pipeline across discovery to late-stage, including in-house and partnered programs in CNS, immunology, and metabolic diseases.

• Major collaborations with global pharma (Neurocrine, Pfizer, Lilly, AbbVie, Centessa) and multi-billion USD milestone and royalty potential.

• Key clinical programs include muscarinic agonists for schizophrenia and bipolar mania, GPR52 agonist, EP4 antagonist for oncology, and OX2 agonist for sleep disorders.

• 2025–2026 catalysts include multiple clinical trial initiations, data readouts, and new licensing deals.